Pfizer
- Market cap
- 159.59B
- P/E (TTM)i
- 36.84
- P/Bi
- 1.87
- EPSi
- 1.36
- Div yieldi
- 6.14%
- 52W posi
- 82%
Anonymous reader poll. Unscientific, not investment advice.
Pfizer ended the session at 28.00, up 1.82%. The company carries a market value of roughly 159.59B, the #133 most valuable US-listed company we track. Income-focused holders are looking at a trailing yield of 6.14% here. Across 19 analysts the consensus rating is Buy, with an average price target of 28.92 (+3%). The shares sit 82% of the way up their 52-week range of 22.57 to 29.21.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 months.
- Recent price momentum is +16.2% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 2.7% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 36.1x | Better than 21% |
| Forward P/E | 14.2x | Better than 63% |
| Price / Sales | 2.5x | Better than 57% |
| P/E vs own 5-yr range | 93rd pctl | Better than 10% |
Growth F
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -14.8% | Better than 2% |
| Net income CAGR (3Y) | -37.2% | Better than 6% |
| Free cash flow CAGR (3Y) | -29.6% | Better than 9% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 74.3% | Better than 87% |
| Operating margin | 27.8% | Better than 82% |
| Net margin | 12.4% | Better than 54% |
| Return on equity | 8.9% | Better than 33% |
| Return on invested capital | 6.2% | Better than 35% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 15.9% | Better than 83% |
| 6-month return | 4.6% | Better than 48% |
| 12-month return (ex latest month) | 15.2% | Better than 51% |
| Distance below 52-week high | 6.2% | Better than 88% |
Financial Health C-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.2x | Better than 36% |
| Debt to assets | 74.0% | Better than 15% |
| Interest coverage | 3.8x | Better than 34% |
| Free cash flow / net income | 116.8% | Better than 54% |
Analyst View D
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 36.8% | Better than 17% |
| Upside to average target | 5.5% | Better than 10% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 27.50
- Open
- 27.62
- Day range
- 27.55 - 28.17
- Avg price
- 27.99
- Volume
- 31.23M
- Turnover
- 874.15M
- Turnover ratei
- 0.55%
- Volume ratioi
- 0.97
- Amplitudei
- 2.26%
- 52-week rangei
- 22.57 - 29.21
Valuation
- P/Ei
- 20.59
- P/E (TTM)i
- 36.84
- P/Bi
- 1.87
- EPSi
- 1.36
- Book value / shi
- 14.95
- Net profit
- 7.75B
- Net assets
- 85.19B
Share structure
- Market cap
- 159.59B
- Float capi
- 159.38B
- Shares out
- 5.70B
- Float sharesi
- 5.69B
Dividend & listing
- Div yield (TTM)i
- 6.14%
- Dividend (TTM)
- 1.72
- Listing date
- 1970-01-01
4.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+22.89M net over the window
Short interest
- Shares short
- 155.20M
- % of floati
- 2.72%
- Days to coveri
- 4.90
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Pfizer (PFE)?
Pfizer last traded at 28.00. The quote on this page refreshes every few seconds while US markets are open.
What is Pfizer's market cap?
About 159.59B.
What is the P/E ratio of Pfizer?
The trailing twelve-month P/E is 36.84. The Valuation tab shows it against the stock's own five-year range.
Does Pfizer pay a dividend?
Yes. The trailing dividend yield is 6.14%. The 2025 payout was up 2.4% from 2024. See the Dividends tab for the full payment history.
Is Pfizer a buy according to analysts?
The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 28.92, which implies 3.3% upside from the current price. This is not investment advice.
What is Pfizer's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Pfizer a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 09:19:58 · For reference only, not investment advice and not tailored to your situation.